People · Operator
Named in public records as an officer, director or promoter · active 2019–2019 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Egalet Corp | — | Pharmaceuticals | Series C | $42.2M | $1.5B | 2019 |
MARK M. STROBECK at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside MARK M. STROBECK on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Timothy P. Walbert | 1 | 3 |
| Robert S Radie | 1 | 2 |
| ANDREA S. HESLIN SMILEY | 1 | 1 |
| JOSEPH P. MCINNIS | 1 | 1 |
| BARBARA A. CARLIN | 1 | 1 |
| MATTHEW P. PAULS | 1 | 1 |
| TODD P. HOLMES | 1 | 1 |
| MEGAN M. TIMMINS | 1 | 1 |
| LUKE P. DUSTER | 1 | 1 |
| PATRICK M. SHEA | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.